Divi's Laboratories Limited

Date: August 10, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

Trading Symbol: **DIVISLAB**

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Scrip Code: **532488**

Dear Sir/ Madam,

Sub: Proceedings of the 36th Annual General Meeting, Voting Results and Consolidated Scrutinizer's Report

Ref: Regulation 30 and 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that the 36th Annual General Meeting (AGM) of the Company was held on August 10, 2026, at 10.00 a.m. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) and the business mentioned in the Notice of 36th AGM dated May 23, 2026 was duly transacted.

In this regard, we hereby submit the following:

1. Summary of proceedings of the 36th AGM along with copy of the Chairman's speech and Managing Director's speech delivered at the AGM as **Annexure – I**;

2. Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as **Annexure – II**;

3. The Consolidated Scrutinizer's Report on remote e-voting and voting at AGM (by electronic means) as **Annexure – III**.

Please note that all the resolutions set out in the Notice of 36th AGM were passed with requisite majority.

This is for your information and records.

Yours faithfully,
For **Divi's Laboratories Limited**
SATISH CHOUDHURY MEKA
Digitally signed by SATISH CHOUDHURY MEKA
Date: 2026.08.10 19:06:48 +05'30'
M. Satish Choudhury
Company Secretary & Compliance Officer

Divi's Laboratories Limited

Summary of proceedings of the 36th Annual General Meeting of Divi's Laboratories Limited held on Monday, August 10, 2026, at 10.00 a.m. (IST) through Video Conferencing /Other Audio-Visual Means

Directors present through Video Conferencing (VC) / Other Audio-Visual Means (OAVM):

S. No.	Name	Designation	Location
1.	Dr. Ramesh B.V. Nimmagadda	Chairman & Independent Director, Chairman of Stakeholders Relationship Committee	Chennai
2.	Dr. Murali K. Divi	Managing Director	Hyderabad
3.	Mr. N.V. Ramana	Executive Director	Hyderabad
4.	Dr. Kiran S. Divi	Whole-time Director & Chief Executive Officer, Chairman of Risk Management and Sustainability Committee	Hyderabad
5.	Ms. Nilima Prasad Divi	Whole-time Director (Commercial)	Hyderabad
6.	Dr. S. Devendra Rao	Whole-time Director (Manufacturing)	Visakhapatnam
7.	Prof. S. Ganapaty	Independent Director and Chairman of Nomination and Remuneration Committee	Visakhapatnam
8.	Prof. Sunaina Singh	Independent Director	Hyderabad
9.	Mr. K.V. Chowdary	Independent Director and Chairman of Audit Committee	Hyderabad
10.	Dr. Rajendra Kumar Premchand	Independent Director	Hyderabad

In attendance of the following persons present through VC / OAVM participated in the meeting:

S. No.	Name	Designation	Location
1.	Mr. Venkatesa Perumallu Pasumarthy	Chief Financial Officer	Hyderabad
2.	Mr. M. Satish Choudhury	Company Secretary & Compliance Officer	Hyderabad
3.	Mr. N.K. Varadarajan	Partner, Price Waterhouse Chartered Accountants LLP, Statutory Auditors	Hyderabad
4.	Mr. V. Bhaskara Rao	Partner, V. Bhaskara Rao & Co., Company Secretaries, Secretarial Auditor & Scrutiniser	Hyderabad
5.	Mr. L. Kishore Babu	Principal Advisor (Finance)	Hyderabad

Members Present:

The 36th Annual General Meeting was attended by 150 members (representing 12,42,61,211 shares) through VC or OAVM.

Proceedings:
Dr. Ramesh B.V. Nimmagadda, Chairman of the Company, chaired the meeting and conducted the proceedings of the meeting. The requisite quorum being present, the Chairman called the meeting to order.

Mr. M. Satish Choudhury, Company Secretary informed the members about general instructions regarding participation and voting at this meeting. He informed that the Annual General Meeting (AGM) was held through VC or OAVM in accordance with the Companies Act, 2013 and circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. Accordingly, the Company has provided the facility for the members for joining the meeting through VC or OAVM. It was informed that the Company has also provided webcast facility to view the live proceedings of the AGM.

It was informed that the Notice of the 36th AGM and the Annual Report for the financial year ended March 31, 2026, have been sent electronically to members whose email addresses are registered with the Company or with the depositories. In addition, physical copies of the Annual Report have been sent to the members who have requested for the same. The Company has sent letters to shareholders whose email addresses are not registered with the Company or depository participants, providing the web link and QR code from where the annual report can be accessed on the Company's website.

The Register of Directors and Key Managerial Personnel, the Register of Contracts or Arrangements in which Directors are interested, were made available electronically for inspection by the members during the AGM.

Members were informed that the Company had provided the facility to cast the votes electronically, on all resolutions set forth in the Notice of AGM; and Members who have not cast their votes electronically and were participating in the meeting can cast their votes during the meeting through the e-voting system (Insta Poll) provided by Kfin Technologies Limited (Kfintech).

The Chairman outlined the pharma industry outlook, and the Managing Director briefed the meeting on the Company's operations during the year 2025-26, during the first quarter of the FY 2026-27 and outlook; beside updating about dividend and CSR initiatives by the Company. A copy of the Chairman's speech and Managing Director's speech are enclosed herewith.

The Company Secretary provided summary of the Statutory Auditor's Report and Secretarial Auditor's Report for the year ended March 31, 2026 and informed that there were no qualifications, observations or adverse comments on financial statements and matters which have any material bearing on the functioning of the Company.

The Annual Report for the year ended March 31, 2026, along with Notice of this meeting, Board's Report, Auditor's Reports, and the Audited Financial Statements of the Company as circulated to the members, were taken as read.

The remote e-voting period commenced at 9 a.m. (IST) on Thursday, August 06, 2026, and the facility was available to the shareholders till 5 p.m. (IST) on Sunday, August 09, 2026. It was informed that there would be no voting by show of hands at the meeting.

It was also informed that the Board of Directors has appointed Mr. V. Bhaskara Rao, Practicing Company Secretary (C.P No. 4182) or failing him Mr. K. Nagarjuna, Practicing Company Secretary (C.P. No. 27893), Partners of M/s. V. Bhaskara Rao & Co., Company Secretaries, Hyderabad, as the Scrutinizer for scrutiny of the votes cast through the remote e-voting platform and e-voting during the AGM.

The following items of business as set out in the Notice convening the 36th Annual General Meeting were commended for Members' consideration and approval:

Sl. No.	Resolutions Description	Type of resolution
Ordinary Business		
1.	To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2026, and the reports of the Board of Directors' and Auditors' thereon.	Ordinary
2.	To declare dividend of ₹30/- per equity share of face value ₹2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2026.	Ordinary
3.	To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.	Ordinary
4.	To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.	Ordinary

The Chairman formally announced e-voting during the Meeting for all those shareholders who have not cast their votes earlier, through Insta Poll provided by Kfintech, in respect of all the resolutions as set out in the Notice convening this AGM.

The Chairman opened the Question and Answers session. The Members registered as speakers asked their queries and expressed their views. The Managing Director summarised his response to the queries of the Members.

The Chairman authorized the Company Secretary to declare the results of the voting and place the results on the website of the Company and on the website of Kfintech at the earliest, besides submitting the same to the Stock Exchanges i.e., NSE and BSE. He informed that the resolutions, as set forth in the Notice, shall be deemed to be passed today (i.e. on August 10, 2026), subject to receipt of requisite number of votes.

Divi's Laboratories Limited

The Chairman announced that all the business set out in the Notice of the AGM has been concluded and a time period of 15 minutes would be available for voting at the meeting on the Kfintech's Insta-poll after which the meeting will stand closed. He thanked the Members for attending the meeting. It was confirmed that the requisite quorum was present throughout the meeting.

The Annual General Meeting was concluded at 11.26 a.m. (IST) on August 10, 2026.

The Scrutinizers' Report was received on August 10, 2026, and accordingly, all the resolutions set out in the Notice of the 36th Annual General Meeting of the Company dated May 23, 2026, were declared as passed with requisite majority.

For Divi's Laboratories Limited

SATISH CHOUDHURY MEKA

Digitally signed by SATISH CHOUDHURY MEKA
Date: 2026.08.10 19:07:37 +05'30'

M. Satish Choudhury
Company Secretary & Compliance Officer

(Enclosures: Chairman's Speech and Managing Director's Speech)

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.
Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854
E-mail : mail@divislabs.com, Website : www.divislabs.com

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854
Registered Office: Divi Towers, 1-72/23(P)/DIVIS/303,
Cyber Hills, Gachibowli, Hyderabad - 500 032, INDIA
Tel: +91-40-6696 6300, Fax: +91-40-6696 6460
E-mail: cs@divislabs.com, Website: www.divislabs.com

36th Annual General Meeting, 10th August 2026

CHAIRMAN'S SPEECH

Dear Shareholders and esteemed members of the Board,

Good morning and a warm welcome to the 36th Annual General Meeting of Divi's Laboratories Limited. I extend my heartfelt greetings to each one of you and sincerely hope that you and your families are in good health.

The Annual Report for the financial year ended 31st March 2026, together with the Notice of the Meeting, the Board's Report, and the Audited Financial Statements of the Company, has been duly circulated. With your permission, I shall take these as read.

As we gather here today, I wish to acknowledge and extend my gratitude to each one of you for your enduring trust and support. On behalf of the Board of Directors, I thank you for your valuable time and participation.

FY 2025–26 was a year of resilience amidst an increasingly dynamic global environment. The pharmaceutical industry remained steady in its path of growth even as geopolitical tensions, evolving trade policies, changing regulatory expectations, and the ongoing realignment of global supply chains influenced business conditions worldwide.

According to IQVIA, the global pharmaceutical market is projected to expand from approximately USD 1.74 trillion in 2025 to USD 2.6 trillion by 2030. Growth is increasingly being driven by specialty medicines and advanced treatment modalities that require high levels of scientific expertise, manufacturing reliability at scale, and consistent commercial execution. Expanding healthcare access across emerging markets, the rising prevalence of chronic diseases, and increasing uptake of lifestyle-changing medicines further support long-term demand.

Peptide therapeutics, estimated to be approximately USD 140 billion in 2025, are now among the fastest-growing segments of the pharmaceutical industry, driven by increasing demand across metabolic disorders, oncology, and other chronic disease therapies. The rapid global adoption of GLP-1 medicines has further accelerated investments across the peptide ecosystem and reinforced the importance of specialised development and manufacturing capabilities.

These developments are fundamentally reshaping pharmaceutical manufacturing. As treatment paradigms become increasingly centred on complex molecules and targeted therapies, the need for reliable, compliant, and scalable manufacturing has become more critical than ever. Across the API industry, competitive advantage is steadily shifting towards differentiated process chemistry, advanced manufacturing technologies, automation, digitalisation, supply assurance, and global regulatory compliance. The API industry, valued at around USD 270 billion in 2025, is thus moving toward process-intensive, high-barrier chemistries and back-integrated manufacturing models.

At the same time, Contract Development and Manufacturing Organisations have evolved from providers of supplemental manufacturing capacity to strategic long-term partners supporting global innovators from development through commercial supply. Reflecting this underlying shift, the global CDMO market is expected to grow from nearly USD 150 billion in 2024 to around USD 290 billion by 2033.

India, with exports contributing more than half of its FY2025-26 pharma revenue, is also well-positioned to benefit from these changes. India's pharmaceutical market is projected to reach USD 120–130 billion by 2030, while the country's CDMO sector is expected to scale nearly fivefold to around USD 10–12 billion over the 2024–2035 period. Furthermore, India's CDMO exports are expected to account for 13–15% of global outsourcing expenditure by 2030. Supported by its strong manufacturing ecosystem, expanding digital and scientific capabilities, regulatory credibility, policy support, and cost competitiveness, India continues to strengthen itself as the preferred global pharmaceutical manufacturing destination.

Against this backdrop, Divi's Laboratories continued to reinforce its position as a trusted global pharmaceutical manufacturer through disciplined execution, manufacturing intensity, customer-centricity, and an unwavering commitment to quality and compliance.

During the year, operations at Unit 3 continued to ramp up, strengthening backward integration and enhancing supply reliability, cost efficiency, and quality control. Other major capital expenditure programmes, supported by long-term customer visibility and aligned with future growth opportunities, are progressing as planned. Together with its long-standing customer relationships, deep chemistry expertise, stringent environmental, health and safety standards, and a culture of continuous improvement, these investments provide a strong foundation for long-term growth. Your Company is prepared to pursue global opportunities while creating sustainable value for all stakeholders. I commend the Management for their dedication to moving the Company forward.

Thank you.

Dr. Ramesh Nimmagadda
Chairman

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854
Registered Office: Divi Towers, 1-72/23(P)/DIVIS/303,
Cyber Hills, Gachibowli, Hyderabad - 500 032, INDIA
Tel: +91-40-6696 6300, Fax: +91-40-6696 6460
E-mail: cs@divislabs.com, Website: www.divislabs.com

36th Annual General Meeting, 10th August 2026

MANAGING DIRECTOR'S SPEECH

Ladies and Gentlemen,

Good morning to each one of you, and a hearty welcome to the 36th Annual General Meeting of Divi's Laboratories Limited.

FY 2025–26 was a year of careful execution, steady progress, and continued investment in capacity expansion and future-ready capabilities for your Company. The global business environment remained volatile, shaped by geopolitical developments, logistics disruptions, and pricing pressures across the pharma value chain. Despite these external uncertainties, Divi's Laboratories remained firmly focused on executing its long-term strategy while continuing to deliver reliably for customers through disciplined capital allocation and resilient operations.

Guided by agile decision-making, meticulous planning, and proactive risk management, your Company successfully navigated these challenges while meeting customer commitments throughout the year. Your Company further strengthened its diversified procurement approach by deepening its domestic sourcing base. Together with extensive work with trusted logistics partners, these initiatives reinforced supply continuity and enabled your Company to respond effectively to dynamic situations.

Your Company's performance reflected the strength of its operating model, manufacturing discipline, long-term customer relationships and sustained investments in capacity, technology, and backward integration. These factors have enabled Divi's to maintain high standards of quality and compliance while enhancing competitiveness.

Your Company also continued to integrate sustainability across its manufacturing facilities and processes. Expanded implementation of Green Chemistry principles, solvent recovery, energy efficiency initiatives, and responsible resource utilisation remained integral to the way Divi's operates. Simultaneously, investments in automation-led process controls and advanced manufacturing platforms further enhanced safety and productivity across the plants. These initiatives are complemented by a resolute commitment to responsible business practices, enabling your Company to create enduring value across stakeholders.

OPERATIONS FOR THE YEAR

During FY 2025–26, your Company achieved several important milestones across its operations. At the Unit 1 manufacturing facility, Hyderabad, a general cGMP inspection by the US FDA was completed successfully, reinforcing your Company's commitment to the highest standards of quality, global compliance, and regulatory readiness.

Your Company's Greenfield Unit 3 facility near Kakinada continued to make significant progress during the year and is becoming an increasingly important part of the internal manufacturing network. The facility further strengthened backward integration through the manufacture of quality starting materials while supporting the transfer of select activities from Units 1 and 2, thereby releasing valuable GMP capacity for new products and customer programmes. Additional blocks at Unit 3 are progressing in line with the Company's capacity plans.

Technology remained a key focus during the year. Your Company also continued to advance capabilities in Continuous Flow Chemistry, Biocatalysis, and Green Chemistry, while progressively integrating these platforms into development and commercial manufacturing. Greater adoption of automation, advanced process analytics, and digital monitoring tools strengthened process safety, minimised variability, and improved manufacturing efficiency. Focused investments are creating future-ready systems that enhance your Company's ability to execute more complex chemistries at scale, while also addressing evolving customer requirements with greater speed, flexibility, and sustainability.

Turning to Custom Synthesis, your Company witnessed healthy traction during the year, with a strong flow of customer interactions and multiple programmes progressing through their planned stages of development. Divi's also continued to expand the manufacturing infrastructure and technical capabilities required to support programmes transitioning into commercial manufacturing.

One of the important milestones achieved during the year was the inauguration of the Peptide Centre of Excellence at Unit 1, further strengthening your Company's differentiated peptide platform. Alongside capacity enhancements across solid- and liquid-phase peptide synthesis, these investments expand Divi's ability to support customers across development and commercial manufacturing as peptide-based therapies gain momentum.

The Nutraceutical segment also recorded a healthy performance during the year. 2026 also marked 20 years of Divi's Nutraceuticals, an important milestone in the evolution of this business. As growing awareness around health, nutrition, and wellness heightens consumer interest in high-quality nutraceutical ingredients, Divi's remains well-aligned to meet growing demand.

Highlights of the operations for the year 2025–26 are:

- Your Company recorded a consolidated total income of ₹11,067 crores during FY 2025-26 as compared to ₹9,712 crores in the previous financial year.
- Profit Before Tax (PBT) for the year stood at ₹3,388 crores.
- Profit After Tax (PAT) for the year stood at ₹2,568 crores.
- Earnings Per Share of ₹2 each amounted to ₹96.75 for the year.
- Out of the total revenue, exports accounted for 89%.

DIVIDEND

Your Board is pleased to recommend a dividend of ₹30 per equity share, i.e., 1,500% for the financial year ended March 31, 2026. The total dividend payout for the year amounts to ₹796.41 crores.

OPERATIONS FOR QUARTER ENDED 30th JUNE 2026

Divi's Laboratories continued to execute steadily across its businesses during the first quarter of FY 2026–27.

The Custom Synthesis business maintained healthy engagement with global pharmaceutical companies across multiple therapeutic areas, supported by a robust pipeline of projects progressing through various stages of development. Divi's continues to work with customers across multiple clinical phases, alongside projects where validation has been completed, and supplies are being aligned with customer-specific regulatory and filing requirements. The Company's three major capital expenditure programmes are nearing completion, with validation activities progressing as planned to support future commercial manufacturing requirements. As products progress through different stages of their lifecycle, from patent-phase opportunities to late-lifecycle programmes, new molecules continue to enter the Company's pipeline, supporting a balanced portfolio.

In peptides, multiple customer programmes advanced across different stages of development during the quarter, while validation activities for several peptide fragments continued to progress. Divi's remains focused on strengthening its peptide manufacturing capabilities to support increasingly complex customer requirements with the highest standards of quality, reliability and execution. Your Company's backward integration depth, alongside its established expertise in complex building blocks and peptide fragments, provides greater control over peptide chemistries, costs, and quality.

The world remained affected by tensions in West Asia, resulting in continued disruption to global shipping routes, port congestion, longer transit times, tight container and tank availability, elevated freight rates, and higher solvent costs. Nonetheless, the resilient sourcing and supply chain framework built over the past several years enabled your Company to continue serving customers throughout the quarter. A geographically diversified supplier base, expanded domestic supplier network, proactive inventory management, and raw material buffer stocks ensured business continuity. Your Company also maintained close coordination with customers and trusted logistics partners to minimise the impact of external disruptions, enabling uninterrupted manufacturing and customer deliveries. Activities at Unit 3 further enhanced supply reliability and operational flexibility across the manufacturing network. While near-term uncertainties arising from global developments continue to warrant close monitoring, your Company's long-term strategy and commitment to reliability remain unchanged. As Divi's focuses on business priorities, it remains equally committed to generating lasting value for the communities it serves.

During the first quarter of the year 2026-27, your Company earned a consolidated total income of ₹3,144 crores, a profit before tax of ₹1,180 crores, and a profit after tax of ₹902 crores.

CSR INITIATIVES

Your Company's commitment to responsible and inclusive growth is reflected in its sustained efforts to strengthen the communities in which it operates. Throughout FY 2025–26, Divi's Laboratories worked with communities across Andhra Pradesh and Telangana states to address essential societal needs, improve access to critical services, and enhance the quality of life, with a particular emphasis on women, children, and rural households.

Key initiatives undertaken during the year include:

- **Safe Drinking Water:** Through Project Sujalam and Project Jalaprasadam, safe drinking water reached over 12.79 lakh beneficiaries across 1,407 locations. Project Jalaprasadam provided clean drinking water to over 5.72 lakh devotees daily across 30 temples, while Project Sujalam served more than 7 lakh individuals across communities.

- **Education:** Infrastructure development and modernisation of educational institutions, digital learning support, scholarship and study material distribution programmes, nutrition initiatives, and access to free health camps positively impacted over 1.10 lakh children across 1,093 schools.

- **Preventive Healthcare:** Healthcare initiatives benefitted over 85,650 individuals across 55 villages through health camps, medical equipment support, and improvements to public healthcare infrastructure.

- **Village development** initiatives reached over 1.31 lakh people across 82 villages through investments in roads, irrigation support, public infrastructure, and community facilities. Support to Swachh Bharat initiatives benefitted approximately 1.82 lakh individuals across 207 locations through sanitation infrastructure and awareness programmes.

- **Environmental Sustainability** programmes supported plantation and ecological development initiatives across 22 locations during the year.

- **Livelihood Enhancement:** Skill development and vocational programmes helped improve opportunities and self-employment among around 500 women and youth across 28 villages.

- **Support for Differently Abled:** Continued assistance for children with special needs through infrastructure support, educational provisions, and specialised programmes across 3 schools.

- **Disaster Management:** Relief and rehabilitation initiatives supported approximately 27,800 individuals across 39 villages affected by natural calamities and emergencies.

Collectively, these initiatives positively impacted more than 18 lakh lives during the year, reaffirming your Company's commitment to creating sustainable social value by contributing to stronger and healthier communities.

CONCLUSION

Ladies and Gentlemen, on behalf of the Board, I extend my sincere appreciation to all employees, customers, business associates, financial institutions, regulatory authorities, government departments and shareholders for their continued trust, confidence, and encouragement. Your steadfast support inspires your Company as it walks towards the next phase of growth.

Thank You.
Dr. Murali K. Divi
Managing Director

ANNEXURE - II

General information about company	
Scrip code	532488
NSE Symbol	DIVISLAB
MSEI Symbol	NOTLISTED
ISIN	INE361B01024
Name of the company	Divi's Laboratories Limited
Type of meeting	AGM
Date of the meeting / last day of receipt of postal ballot forms (in case of Postal Ballot)	10-08-2026
Start time of the meeting	10:00 AM
End time of the meeting	11:26 AM

Scrutinizer Details	
Name of the Scrutinizer	V. Bhaskara Rao
Firms Name	V. Bhaskara Rao & Co
Qualification	CS
Membership Number	5939
Date of Board Meeting in which appointed	23-05-2026
Date of Issuance of Report to the company	10-08-2026

Voting results	
Record date	03-08-2026
Total number of shareholders on record date	233030
No. of shareholders present in the meeting either in person or through proxy	
a) Promoters and Promoter group	0
b) Public	0
No. of shareholders attended the meeting through video conferencing	
a) Promoters and Promoter group	4
b) Public	146
No. of resolution passed in the meeting	4
Disclosure of notes on voting results	

SATISH CHOUDHURY MEKA

Digitally signed by SATISH CHOUDHURY MEKA
Date: 2026.08.10 19:08:10 +05'30'

<table>
<tr><th colspan="9">Resolution(1)</th></tr>
<tr><td colspan="4">Resolution required: (Ordinary / Special)</td><td colspan="5">Ordinary</td></tr>
<tr><td colspan="4">Whether promoter/promoter group are interested in the agenda/resolution?</td><td colspan="5">No</td></tr>
<tr><td colspan="4">Description of resolution considered</td><td colspan="5">To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2026, and the reports of the Board of Directors' and Auditors' thereon.</td></tr>
<tr><td>Category</td><td>Mode of voting</td><td>No. of shares held</td><td>No. of votes polled</td><td>% of Votes polled on outstanding shares</td><td>No. of votes – in favour</td><td>No. of votes – against</td><td>% of votes in favour on votes polled</td><td>% of Votes against on votes polled</td></tr>
<tr><td colspan="2"></td><td>(1)</td><td>(2)</td><td>(3)=[(2)/(1)]*100</td><td>(4)</td><td>(5)</td><td>(6)=[(4)/(2)]*100</td><td>(7)=[(5)/(2)]*100</td></tr>
<tr><td rowspan="4">Promoter and Promoter Group</td><td>E-Voting</td><td rowspan="3">137735090</td><td>137567000</td><td>99.878</td><td>137567000</td><td>0</td><td>100</td><td>0</td></tr>
<tr><td>Poll</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr>
<tr><td>Postal Ballot (if applicable)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr>
<tr><td>Total</td><td>137735090</td><td>137567000</td><td>99.878</td><td>137567000</td><td>0</td><td>100</td><td>0</td></tr>
<tr><td rowspan="4">Public- Institutions</td><td>E-Voting</td><td rowspan="3">103776398</td><td>95373531</td><td>91.9029</td><td>95263620</td><td>109911</td><td>99.8848</td><td>0.1152</td></tr>
<tr><td>Poll</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr>
<tr><td>Postal Ballot (if applicable)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr>
<tr><td>Total</td><td>103776398</td><td>95373531</td><td>91.9029</td><td>95263620</td><td>109911</td><td>99.8848</td><td>0.1152</td></tr>
<tr><td rowspan="4">Public- Non Institutions</td><td>E-Voting</td><td rowspan="3">23957092</td><td>2306270</td><td>9.6267</td><td>2306174</td><td>96</td><td>99.9958</td><td>0.0042</td></tr>
<tr><td>Poll</td><td>271100</td><td>1.1316</td><td>271100</td><td>0</td><td>100</td><td>0</td></tr>
<tr><td>Postal Ballot (if applicable)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr>
<tr><td>Total</td><td>23957092</td><td>2577370</td><td>10.7583</td><td>2577274</td><td>96</td><td>99.9963</td><td>0.0037</td></tr>
<tr><td colspan="2">Total</td><td>265468580</td><td>235517901</td><td>88.7178</td><td>235407894</td><td>110007</td><td>99.9533</td><td>0.0467</td></tr>
<tr><td colspan="7">Whether resolution is Pass or Not.</td><td colspan="2">Yes</td></tr>
<tr><td colspan="7">Disclosure of notes on resolution</td><td colspan="2"></td></tr>
</table>

Details of Invalid Votes	
Category	No. of Votes
Promoter and Promoter Group	
Public Insitutions	
Public - Non Insitutions	

Resolution(2)								
Resolution required: (Ordinary / Special)				Ordinary				
Whether promoter/promoter group are interested in the agenda/resolution?				No				
Description of resolution considered				To declare dividend of Rs.30/- per equity share of face value Rs.2/- each (i.e.@ 1,500%) for the financial year ended March 31, 2026.				
Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)= [(2)/(1)]*100	(4)	(5)	(6)= [(4)/(2)]*100	(7)= [(5)/(2)]*100
Promoter and Promoter Group	E-Voting	137735090	137567000	99.878	137567000	0	100	0
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	137735090	137567000	99.878	137567000	0	100	0
Public- Institutions	E-Voting	103776398	95407530	91.9357	95407530	0	100	0
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	103776398	95407530	91.9357	95407530	0	100	0
Public- Non Institutions	E-Voting	23957092	2306570	9.6279	2306475	95	99.9959	0.0041
	Poll		271100	1.1316	271100	0	100	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	23957092	2577670	10.7595	2577575	95	99.9963	0.0037
	Total	265468580	235552200	88.7307	235552105	95	100	0
Whether resolution is Pass or Not.							Yes	
Disclosure of notes on resolution								

Details of Invalid Votes	
Category	No. of Votes
Promoter and Promoter Group	
Public Insitutions	
Public - Non Insitutions	

Resolution(3)								
Resolution required: (Ordinary / Special)				Ordinary				
Whether promoter/promoter group are interested in the agenda/resolution?				No				
Description of resolution considered				To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.				
Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)= [(2)/(1)]*100	(4)	(5)	(6)= [(4)/(2)]*100	(7)= [(5)/(2)]*100
Promoter and Promoter Group	E-Voting	137735090	137567000	99.878	137567000	0	100	0
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	137735090	137567000	99.878	137567000	0	100	0
Public- Institutions	E-Voting	103776398	95405722	91.9339	94676004	729718	99.2351	0.7649
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	103776398	95405722	91.9339	94676004	729718	99.2351	0.7649
Public- Non Institutions	E-Voting	23957092	2306270	9.6267	2306090	180	99.9922	0.0078
	Poll		271100	1.1316	271100	0	100	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	23957092	2577370	10.7583	2577190	180	99.993	0.007
Total		265468580	235550092	88.7299	234820194	729898	99.6901	0.3099
Whether resolution is Pass or Not.							Yes	
Disclosure of notes on resolution								

Category	No. of Votes
Promoter and Promoter Group	
Public Insitutions	
Public - Non Insitutions	

Resolution(4)								
Resolution required: (Ordinary / Special)				Ordinary				
Whether promoter/promoter group are interested in the agenda/resolution?				No				
Description of resolution considered				To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.				
Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)= [(2)/(1)]*100	(4)	(5)	(6)= [(4)/(2)]*100	(7)= [(5)/(2)]*100
Promoter and Promoter Group	E-Voting	137735090	137567000	99.878	137567000	0	100	0
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	137735090	137567000	99.878	137567000	0	100	0
Public- Institutions	E-Voting	103776398	95405722	91.9339	94929367	476355	99.5007	0.4993
	Poll		0	0	0	0	0	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	103776398	95405722	91.9339	94929367	476355	99.5007	0.4993
Public- Non Institutions	E-Voting	23957092	2306270	9.6267	2306101	169	99.9927	0.0073
	Poll		271100	1.1316	271100	0	100	0
	Postal Ballot (if applicable)		0	0	0	0	0	0
	Total	23957092	2577370	10.7583	2577201	169	99.9934	0.0066
Total		265468580	235550092	88.7299	235073568	476524	99.7977	0.2023
Whether resolution is Pass or Not.							Yes	
Disclosure of notes on resolution								

Details of Invalid Votes	
Category	No. of Votes
Promoter and Promoter Group	
Public Insitutions	
Public - Non Insitutions	

V. BHASKARA RAO & CO.
COMPANY SECRETARIES

H.No. 6-3-347/1 & 2, Flat No. 104,
Second Floor, Megasri Classics,
Opposite to Suvidha Hospital,
Dwarakapuri Colony, Punjagutta,
Hyderabad - 500082, Telangana.
Office : 9392369579
Mobile : 9392399570
E-mail : bhaskararaoandco@gmail.com

Consolidated Scrutinizer's Report for Remote E-Voting and E-Voting during the AGM

[Pursuant to Section 108 of the Companies Act, 2013 ("the Act") and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended ("the Rules") read with Ministry of Corporate Affairs' (MCA) General Circular No. 03/2025 dated 22nd September 2025 and Regulation 44 of SEBI (LODR), Regulations, 2015]

To
Dr. Ramesh B.V. Nimmagadda
Chairman
Divi's Laboratories Limited
CIN: L24110TG1990PLC011854
1-72/23(P)/DIVIS/303, Divi Towers,
Cyber Hills, Gachibowli,
Hyderabad-500032.

The 36th Annual General Meeting ("AGM") of the Equity Shareholders of **Divi's Laboratories Limited ('the Company')** having its Registered Office at 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad-500032, Telangana, was held on Monday, August 10, 2026 at 10.00 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means("OAVM").

Dear Sir,

I, V. Bhaskara Rao, Partner of V. Bhaskara Rao & Co., Company Secretaries, having office at H.No. 6-3-347/1 & 2, Flat No. 104, Second Floor, Megasri Classics, Opposite to Suvidha Hospital, Dwarakapuri Colony, Punjagutta, Hyderabad – 500082, Telangana, India, was appointed as Scrutinizer for the purpose of scrutinizing the e-voting process (remote e-voting) and e-voting during the AGM through VC /OAVM under the provisions of Section 108 of the Companies Act, 2013 ("the Act") read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, read with Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in compliance with framework issued by the Ministry of Corporate Affairs through its circulars and the Secretarial Standards on General Meetings (SS-2) issued by the Institute of Company Secretaries of India, on the below mentioned resolution(s) as provided in the notice of Annual General Meeting dated May 23, 2026, ("AGM Notice").

I submit my report as under:

1. The AGM Notice dated May 23, 2026, as confirmed by the Company was sent to the shareholders in respect of the below mentioned resolutions passed at the AGM of the Company, through electronic mode to those Members whose email addresses are registered with the Company/ Depositories, in compliance with the latest MCA General

V. Bhaskara Rao & Co. FCS No.5939 CP No. 4182 Hyderabad Company Secretaries

2. The Shareholders holding shares as on the "cut off" date i.e. August 03, 2026 were entitled to vote on the resolutions.

3. The Company had appointed KFin Technologies Limited ("KFin") as the service provider, for executing the facility of Remote E-voting and E-voting during the AGM to the shareholders of the Company. The Remote E-voting period for the business to be transacted at the AGM commenced from Thursday, August 06, 2026 from 9.00 A.M. (IST) and ended on Sunday, August 09, 2026 at 5.00 P.M. (IST). The Remote E-voting facility was unblocked by me on August 09, 2026 at 5.00 P.M. (IST).

4. The Company had also provided the e-voting facility during the AGM for the shareholders who have not casted their votes during the remote e-voting process. After seeking permission from the Chairman of the Company, e-voting during the AGM was closed/blocked in the presence of two witnesses who are not in the employment of the Company.

5. Subsequent to the completion of e-voting process at the 36th AGM, the votes cast by the shareholders were diligently scrutinized by me. The votes cast at the AGM were reconciled with the records maintained by KFin and with the authorizations lodged with the Company.

6. In respect of Remote E-Voting, the details containing, inter-alia, list of equity shareholders, who voted "For" and "Against" were downloaded from the e-voting website of KFin (https://evoting.kfintech.com/).

7. The Electronic data and relevant records of Voting shall remain in my safe custody until Chairman considers, approves and signs the Minutes of the aforesaid AGM and the same shall be handed over to the Company Secretary for safe custody.

8. The Management of the Company is responsible to ensure compliance with the requirements of the Act and Rules relating to remote e-voting prior to AGM and e-voting during the AGM on the resolutions contained in the AGM Notice. My responsibility as Scrutinizer for the remote e-voting and e-voting during the 36th AGM is restricted to making a Scrutinizer's Report of the votes cast in favour or against the resolutions.

9. I have completed the formalities of e-voting of the 36th AGM. I hereby submit my report (**Annexed**) and you may accordingly declare the results of the voting.

V. Bhaskara Rao & Co.
FCS No.5939
CP No. 4182
Hyderabad
Company Secretaries

All the resolutions stated in the AGM Notice were duly passed on the basis of consolidated results (i.e. Remote e-voting and e-voting during the 36th AGM) with requisite majority.

Thanking You,

Yours faithfully

For V. Bhaskara Rao & Co.
Company Secretaries

V.B

V.Bhaskara Rao
Partner
C.P.No: 4182, FCS No.5939
Peer Review No.8156/2026
ICSI Unique Code: P2025TS104600
UDIN: F005939H001064271

V. Bhaskara Rao & Co. Company Secretaries FCS No.5939 CP No. 4182 Hyderabad

S.H.K.

Witness : S. Hari Kishore Babu

K. Tirupathi

K. Tirupathi

Place: Hyderabad
Date: August 10, 2026

Enclosed: Annexure

ANNEXURE

Resolution 1: To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2026 and the reports of the Board of Directors' and Auditors' thereon

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1480	235136794	99.84
E-voting (During AGM)	65	271100	00.12
Total	1545	235407894	99.95

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	12	110007	00.05
E-voting (During AGM)	0	0	00.00
Total	12	110007	00.05

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	72535
E-voting (During AGM)	0	0
Total	11	72535

(iv)Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	6	64824
E-voting (During AGM)	4	5980
Total	10	70804

V. Bhaskara Rao & Co. FCS No.5939 CP No. 4182 Hyderabad Company Secretaries

Resolution 2: To declare dividend of ₹30/- per equity share of face value ₹2/- each (i.e.@ 1,500%) for the financial year ended March 31, 2026.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1487	235281005	99.88
E-voting (During AGM)	65	271100	00.12
Total	1552	235552105	100.00

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	8	95	00.00
E-voting (During AGM)	0	0	00.00
Total	8	95	00.00

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	72535
E-voting (During AGM)	0	0
Total	11	72535

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	3	30525
E-voting (During AGM)	4	5980
Total	7	36505

V. Bhaskara Rao & Co. Company Secretaries FCS No.5939 CP No. 4182 Hyderabad

Resolution 3: To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1437	234549094	99.57
E-voting (During AGM)	65	271100	00.12
Total	1502	234820194	99.69

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	73	729898	00.31
E-voting (During AGM)	0	0	00.00
Total	73	729898	00.31

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	72535
E-voting (During AGM)	0	0
Total	11	72535

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	5	32633
E-voting (During AGM)	4	5980
Total	9	38613

V. Bhaskara Rao & Co. FCS No.5939 CP No. 4182 Hyderabad Company Secretaries

Resolution 4: To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1465	234802468	99.68
E-voting (During AGM)	65	271100	00.12
Total	1530	235073568	99.80

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	42	476524	00.20
E-voting (During AGM)	0	0	00.00
Total	42	476524	00.20

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	72535
E-voting (During AGM)	0	0
Total	11	72535

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	5	32633
E-voting (During AGM)	4	5980
Total	9	38613

V. Bhaskara Rao & Co. FCS No.5939 CP No. 4182 Hyderabad Company Secretaries

Soft copy of the list of equity shareholders who voted **"FOR"** and **"AGAINST"** for each resolution, along with other relevant registers and records, shall be emailed to the Company Secretary after the announcement of the results by the Company.

Thanking you

Yours faithfully,

For V. Bhaskara Rao & Co.
Company Secretaries

Witness : S. Hari Kishore Babu

K. Tirupathi

V. Bhaskara Rao & Co. Company Secretaries FCS No.5939 CP No. 4182 Hyderabad

V.Bhaskara Rao
Partner
C.P.No: 4182, FCS No.5939
Peer Review No.8156/2026
ICSI Unique Code: P2025TS104600
UDIN:F005939H001064271

Place: Hyderabad
Date: August 10, 2026